111, Inc. is classed by the SEC under Retail-Drug Stores and Proprietary Stores (industry code 5912), based in Shanghai. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $1.8 billion and a loss of $9 million (its filed statements).
Retail businessRetail-Drug Stores and Proprietary StoresShanghaifilings since 20187 of 9 filed, 2 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a retail business: prior from its industry code (SEC 5912, Retail-Drug Stores and Proprietary Stores); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 4.1 out of ten, 7 of 9 metrics filed and 2 estimated: past 4.5 out of ten, present 4.1 out of ten, future 3.6 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 3.6 out of ten. 1 warning event since 2018; the latest 2024-04-30. 36th percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 6.1 out of ten. +34.5% a year over 10 filed years; profitable in 0 of 10. 61st percentile among 16 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 3.8 out of ten. CrossAssetData estimate 3.8/10, confidence 35 of 100 (one part). 38th percentile among 18 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Financial health (present): 2.6 out of ten. Leverage 133%: owes 133¢ per asset dollar. 26th percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 3.9 out of ten. bottom 39% of 18 in its family; net margin -0.2%. 39th percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 7.5 out of ten. CrossAssetData estimate 7.5/10, confidence 35 of 100 (one part). 75th percentile among 13 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Room to expand (future): 4.2 out of ten. bottom 42% of 18 in its family for room to expand. 42nd percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 2.0 out of ten. bottom 20% of 16 in its family for growth drivers. 20th percentile among 16 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 5.4 out of ten. top 46% of 15 in its family for expectations against reality. 54th percentile among 15 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 20-F filed 2026-04-30 for the period ended 2025-12-31 (on EDGAR). Newest filing: Form 4, 2026-09-29. Filings on record since 2018. Read from EDGAR 2026-10-12.
Where the revenue comes from
Product and service lines in fiscal 2025: Drugs 92%, Nutritional Supplements 3%, Business to Consumer B2c Business 2%, Medical Supplies and Devices 1%, Service 1%, Mp Service under 1%. As tagged in its annual report (Form 20-F, filed 2026-04-30).
Who runs it
Chen, Yang Luke (director); Sun, Jian David (director); Luo, Jun Justin (director); Teo, Nee Chuan (director); Gang, Yu (director); Liu, Junling (director). 6 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.